3692 — Hansoh Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapHigh Flyer

Annual income statement for Hansoh Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	9,935	9,382	10,104	12,261	15,028
Cost of Revenue
Gross Profit	9,065	8,512	9,071	11,144	13,509
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,582	6,376	6,271	7,169	8,475
Operating Profit	3,353	3,007	3,833	5,092	6,554
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	3,300	2,948	3,766	5,085	6,551
Provision for Income Taxes
Net Income After Taxes	2,713	2,584	3,278	4,372	5,555
Net Income Before Extraordinary Items
Net Income	2,713	2,584	3,278	4,372	5,555
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	2,654	2,584	3,278	4,372	5,556
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.442	0.434	0.543	0.739	0.928
Dividends per Share